https://www.jnj.com/innovativemedicine/canada/health-canada-authorizes-tecvaylitm-teclistamab-injection
Approval for TECVAYLITM, a subcutaneously administered therapy, is based on results from the Phase 1/2 MajesTEC-1 study that showed deep and durable responses...
health canadamultiple myelomatecvaylirelapsedrefractory
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT06465316&r=1
Testing Teclistamab (TECVAYLI) in Combination with Iberdomide for Relapsed or Refractory Multiple Myeloma
testingteclistamabtecvaylicombinationiberdomide
https://www.gesundheitsinformation.de/teclistamab-tecvayli-bei-fortgeschrittenem-multiplem-myelom.html
Teclistamab (Handelsname Tecvayli) ist seit August 2023 zur Behandlung eines multiplen Myeloms zugelassen.
teclistamabtecvaylibei